SCRI-huCAR19v1

SCRI-huCAR19v1 is an autologous chimeric antigen receptor T cell (CAR-T) therapy developed by Seattle Children's Hospital. It utilizes a fully human binding domain targeting the B-lymphocyte antigen CD19, which is expressed on the surface of leukemia and lymphoma cells. The therapy involves collecting T cells from the patient and genetically engineering them to express a CAR that recognizes CD19. This design aims to reduce immune rejection and improve persistence of CAR-T cells in patients. SCRI-huCAR19v1 is classified as a second-generation CAR-T product incorporating a costimulatory domain (likely 4-1BB) for enhanced efficacy and durability. Its primary indications are relapsed or refractory leukemia and lymphoma in pediatric and young adult populations[1][2][3][8].

Other names

SCRI-huCAR19v1SCRI-huCAR-19v1SCRI-huCAR 19v1second generation 4 1BBζ CD19-Her2tG